You are here
Nova Pharmaceutical Corp
UEI: N/A
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
CHARACTERIZATION OF KAINATE & AMPA RECEPTOR ANTAGONIST
Amount: $49,669.00STROKE IS THE MOST PROMINENT CNS DISORDER IN THE UNITED STATES AS WELL AS THE LEADING CAUSE OF DISABILITY AND THE THIRD LEADING CAUSE OF DEATH. HOWEVER, THERE ARE NO EFFECTIVE TREATMENTS AVAILABLE TO ...
SBIRPhase I1991Department of Health and Human Services -
IDENTIFICATION OF SIGMA ANTAGONISTS
Amount: $49,911.00DOPAMINE (D2) RECEPTOR ANTAGONISTS SUCH AS HALOPERIDOL AND CHLORPROMAZINE ARE MOST COMMONLY USED TO TREAT SCHIZOPHRENIA. HOWEVER, BOTH ACUTE AND CHRONIC ADMINISTRATION OF THESE DRUGS CAN RESULT IN THE ...
SBIRPhase I1991Department of Health and Human Services -
DEVELOPMENT OF ENDOTHELIN-1 ANTAGONISTS
Amount: $47,000.00ENDOTHELIN-1 (ET-1), A 21 AMINO ACID PEPTIDE, ACTING AT SPECIFIC RECEPTORS IN VASCULAR TISSUES HAS BEEN DEMONSTRATED TO INITIATE SUCH PHYSIOLOGICAL RESPONSES AS: DECREASES/INCREASES IN SYSTEMIC ARTERI ...
SBIRPhase I1991Department of Health and Human Services -
DEVELOPMENT OF CORTICOTROPIN-RELEASING FACTOR ANTAGONISTS
Amount: $447,349.00CORTICOTROPIN-RELEASING FACTOR (CRF), A 41-AMINO ACID PEPTIDE, ACTING AT SPECIFIC RECEPTORS IN THE BRAIN AND PITUITARY HAS BEEN DEMONSTRATED TO INITIATE BEHAVIORAL, PHYSIOLOGICAL AND NEUROENDOCRINE RE ...
SBIRPhase II1990Department of Health and Human Services -
NOVEL CEREBROPROTECTIVE AGENTS
Amount: $49,159.00THERE CURRENTLY EXISTS NO EFFECTIVE PROPHYLACTIC OR POST-HOC PHARMACOTHERAPY FOR MINIMIZING ISCHEMIA-INDUCED NEURONAL DAMAGE. MORE THAN ONE MILLION PEOPLE IN AMERICA ARE BELIEVED TO SUFFER NEURONAL DA ...
SBIRPhase I1990Department of Health and Human Services -
INTERLEUKIN 1 REGULATION OF BRADYKININ RECEPTORS
Amount: $49,611.00BRADYKININ (BK), SYNTHESIZED FOLLOWING MANY PATHOLOGICAL INSULTS, CAUSES SMOOTH MUSCLE CONTRACTION, INCREASED VASCULAR PERMEABILITY, AND STIMULATION OF NEURONAL PAIN RECEPTORS, ACTIONS GENERALLY MEDIA ...
SBIRPhase I1989Department of Health and Human Services -
NOVEL APPETITE SUPPRESSANTS: DISCOVERY AND DEVELOPMENT
Amount: $50,000.00THE SEARCH FOR A PHARMACOLOGICAL AGENT THAT WILL FACILITATE WEIGHT REDUCTION REMAINS AS ONE OF THE MOST CHALLENGING AREAS OF DRUG DEVELOPMENT. ANIMAL AND HUMAN DATA PROVIDE SOUND EVIDENCE THAT BODY WE ...
SBIRPhase I1988Department of Health and Human Services -
GABA(B) RECEPTOR AGONISTS AND ANTAGONISTS
Amount: $50,000.00EVIDENCE SUGGESTS RECEPTORS MEDIATING CNS RESPONSES TO -AMINOBUTYRIC ACID (GABA) ARE HETEROGENEOUS AND THE DESIGNATIONS OF GABA(A) AND GABA(B) HAVE BEEN ADVANCED TO DIFFERENTIATE MAJOR RECEPTOR SUBTYP ...
SBIRPhase I1988Department of Health and Human Services -
NONCOMPETITIVE NMDA RECEPTOR ANTAGONISTS
Amount: $46,000.00SUBSTANTIAL EVIDENCE INDICATES THAT EXCITATORY AMINO ACID (EAA) NEUROTRANSMISSION PLAYS A ROLE IN THE PATHOPHYSIOLOGY OF EPILEPSY, NEURODEGENERATIVE DISORDERS AND THE NEURONAL DAMAGE THAT OCCURS FOLLO ...
SBIRPhase I1988Department of Health and Human Services -
DEVELOPMENT OF CORTICOTROPIN-RELEASING FACTOR ANTAGONISTS
Amount: $46,000.00N/A
SBIRPhase I1988Department of Health and Human Services